The global market for therapeutics targeting IgG4-related disease is witnessing substantial expansion. Driven by an rising prevalence of these inflammatory conditions and the availability of novel treatment options, the market is poised for remarkable opportunities in the near future. Key contributors stimulating this expansion include a growing re